## Psychedelics and Therapeutic Neuroscience

The return of psychedelics to mainstream science and medicine is one of the more unexpected developments since 2018. Substances that were banned, stigmatized, and pushed to the cultural margins for half a century are now the subject of rigorous clinical trials, FDA breakthrough therapy designations, and serious institutional investment.

### What Has Changed Since 2018

The book explored cognitive modification through [Limitless](/md-files/movies_limitless.md) and the [Smart Drugs and Cognitive Enhancement](/md-files/est_smart_drugs.md) page, focusing on nootropics and the pressure to enhance performance. Psychedelics represent a different angle on the same underlying question — altering brain function with chemical tools — but with a therapeutic rather than competitive orientation.

Psilocybin (the active compound in "magic mushrooms") has shown remarkable results in clinical trials for treatment-resistant depression, anxiety, PTSD, and addiction. MDMA-assisted therapy for PTSD advanced through Phase 3 clinical trials, though the regulatory path has been more complicated than advocates hoped — the FDA declined to approve it in 2024, requesting additional data, highlighting the tension between promising results and regulatory rigor. Ketamine, already a legal anesthetic, has been repurposed for depression treatment and is available in specialized clinics across the US.

Multiple US cities and the state of Oregon have decriminalized or legalized psilocybin for supervised therapeutic use. Australia approved clinical use of psilocybin and MDMA in 2023. The policy landscape is shifting rapidly, though unevenly.

Venture capital has entered the space aggressively. Companies like Compass Pathways, Atai Life Sciences, and MindMed are publicly traded and pursuing psychedelic-based therapies as commercial products. This influx of capital has accelerated research but also raised concerns about the commercialization of substances with deep cultural and spiritual histories.

### Why It Matters

The indigenous knowledge question is significant and uncomfortable. Psilocybin, ayahuasca, mescaline, and other psychedelics are not new substances — they have been used in indigenous spiritual and healing practices for centuries or millennia. The Western "rediscovery" framing erases these histories and raises questions about cultural appropriation, biopiracy, and who profits from indigenous knowledge. The book's [Religion, Belief, and Technology](/md-files/rei_religion_belief_technology.md) framework — explored through [Contact](/md-files/movies_contact.md) — is directly relevant: these substances sit at the intersection of science, spirituality, and ways of knowing that do not fit neatly into Western empirical categories.

The [Power, Privilege, and Access](/md-files/rei_power_privilege_access.md) dimension is also clear. Supervised psychedelic therapy sessions can cost thousands of dollars. If these treatments work — and the evidence is increasingly strong that they do for certain conditions — who will have access? The same equity questions that apply to every medical breakthrough apply here, amplified by the regulatory complexity of controlled substances.

And the [Hype vs. Reality](/md-files/ntf_hype_vs_reality.md) discipline matters. Psychedelics are generating genuine excitement in the scientific community, but they are also attracting the kind of utopian narrative — "these substances could solve the mental health crisis" — that the book warns against. They are not a panacea. They work best in therapeutic contexts with trained professionals. The gap between what the science shows and what the culture is promising is a space where careful, assumption-counting thinking is essential.

### Explore Further

- [Smart Drugs and Cognitive Enhancement](/md-files/est_smart_drugs.md) — the book's treatment of cognitive modification
- [Power, Privilege, and Access](/md-files/rei_power_privilege_access.md) — who will have access to these therapies
- [Religion, Belief, and Technology](/md-files/rei_religion_belief_technology.md) — the spiritual and cultural dimensions
- [Hype vs. Reality](/md-files/ntf_hype_vs_reality.md) — separating promising science from utopian claims
- [Informed Consent and Autonomy](/md-files/rei_informed_consent.md) — consent in altered states of consciousness
- [At what point does upgrading a human become creating a different kind of human?](/md-files/ceq_upgrading_humans.md) — the boundary question